Redeye updates its view of Egetis the Q2 report and recent events in the company.
Solteq’s Q2 results were quite weak and both revenue and profitability fell below our estimates.
Redeye comments on Artificial Solutions Q2’2023 report.
Redeye comments on Better Collective’s Q2-results which came in stronger than expected with solid pe...
Redeye resumes coverage after NeoDynamics’ rights issue.
Redeye provides an update on Kontigo Care following its Q2 2023 report.
Redeye comments on Ultimovacs’ Q2 2023 report, following a quarter in which the company’s share pric...
Redeye comments on Evaxion's second quarter report of 2023.
Redeye updates on GiG following its Q2-results which came in stronger than expected driven by strong...
Redeye updates its view on Flexion Mobile following its Q2 2023 report.
Q2 numbers reflect transformation process... ...with e.
Obducat AB (publ) (”Obducat” eller ”Bolaget”) har under årets andra kvartal uppvisat en hög aktivite...
Windon Energy Group meddelade den 21 augusti år 2023 att bolaget tecknat sitt första avtal om försäl...
Med årets andra delårsrapport publicerad står det klart att Lucky Games levererade rekordintäkter fö...
Redeye comments on the new study showing that ColdZyme reduces viral load by more than 99% when appl...
Sales -1% and adj. EBITA -14% vs. ABGSCe Weakness in DOFAB, Nordbutiker; temporary higher costs in o...
Redeye endorses today’s news that the first healthy volunteers have been dosed in the second part of...
We cut '23e-'25e EBITDA by 5-1% Expect some additional implementation costs in Q2 '23e-'24e EV/EBITA...
Redeye endorses the positive results from Nanexa’s clinical phase I trial with NEX-20, a long-acting...
IRLAB has secured full global rights ownership of mesdopetam, the company’s leading asset, which was...
